Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Status:
Completed
Trial end date:
2019-08-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab
SC) as maintenance treatment in participants with moderately to severely active CD who
achieved clinical response following administration of vedolizumab intravenous (vedolizumab
IV) induction therapy.